Legendary Stock Picker Eric Fry Reveals 7 Stocks to Buy and Hold Forever in 2025
Legendary Stock Picker Eric Fry Reveals 7 Stocks to Buy and Hold Forever in 2025

CCCC Stock Earnings: C4 Therapeutics Misses EPS, Misses Revenue for Q1 2024

C4 Therapeutics just reported results for the first quarter of 2024

By InvestorPlace Earnings May 8, 2024, 1:54 pm EDT
CCCC stock - CCCC Stock Earnings: C4 Therapeutics Misses EPS, Misses Revenue for Q1 2024

Source: iQoncept / Shutterstock

C4 Therapeutics (NASDAQ:CCCC) just reported results for the first quarter of 2024.

  • C4 Therapeutics reported earnings per share of -41 cents. This was below the analyst estimate for EPS of -35 cents.
  • The company reported revenue of $3.04 million.
  • This was 62.48% worse than the analyst estimate for revenue of $8.10 million.

InvestorPlace Earnings is a project that leverages data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at editor@investorplace.com.

Article printed from InvestorPlace Media, https://investorplace.com/earning-results/2024/05/cccc-stock-earnings-c4-therapeutics-for-q1-of-2024/.

©2025 InvestorPlace Media, LLC